{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:17:08Z","timestamp":1784125028468,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Centrally located lung tumors present treatment challenges given their proximity to mediastinal structures including the central airway, esophagus, major vessels, and heart. Therapeutic options can be limited for medically inoperable patients, particularly if they have received previous thoracic radiotherapy. High dose rate (HDR) brachyablation was developed to improve the therapeutic ratio for patients with central lung tumors. The purpose of this study is to report initial safety and efficacy outcomes with this treatment for central lung malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From September 2015 to August 2019, a total of 25 patients with 37 pulmonary tumors were treated with percutaneous HDR brachyablation. Treatment was delivered by a multi-disciplinary team of interventional radiologists, pulmonologists, and radiation oncologists. Twenty-three patients received a median dose of 21.5\u00a0Gy (range 15\u201327.5) in a single fraction, whereas two patients received median dose of 24.75\u00a0Gy (range 24\u201325.5) over 2\u20133 fractions. Tumor local control (LC) was evaluated by Response Evaluation Criteria in Solid Tumors v1.1. Treatment-related toxicities were graded by Common Terminology Criteria for Adverse Events v5.0, with adverse events less than 90\u00a0days defined as acute, and those occurring later were defined as late. LC, progression-free survival (PFS), and overall survival (OS) rates were estimated by the Kaplan\u2013Meier method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 37 treated tumors, 88% were metastatic. Tumor location was central and ultra-central in 24.3% and 54.1%, respectively. Average tumor volume was 11.6 cm<jats:sup>3<\/jats:sup> (SD 12.4, range 0.57\u201362.8). Median follow-up was 19\u00a0months (range 3\u201348). Two\u2013year LC, PFS, and OS were 96.2%, 29.7%, and 65.5%, respectively. Thirteen of 39 (33.3%) catheter implantation procedures were associated with trace minor pneumothorax requiring no intervention, 1 (2.5%) procedure with minor radiographic pulmonary hemorrhage, and 4 (10.3%) with major pneumothorax requiring chest tube insertions. All procedural complications resolved within 24\u00a0h from treatment. Acute grade 1\u20132 toxicity was identified in 4 patients, whereas none developed late toxicity beyond 90\u00a0days of follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Percutaneous HDR brachyablation is a safe and promising treatment option for centrally located primary and metastatic lung tumors. Future comparisons with stereotactic body radiotherapy and other ablative techniques are warranted to expand multi-disciplinary management options.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-021-01826-1","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T21:02:38Z","timestamp":1623099758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation"],"prefix":"10.1186","volume":"16","author":[{"given":"Stephanie M.","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereidoun","family":"Abtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Moghanaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Genshaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Kamrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja","family":"Venkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4916-5047","authenticated-orcid":false,"given":"Albert J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"issue":"2 Suppl 1","key":"1826_CR1","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.prro.2013.01.066","volume":"3","author":"N Bi","year":"2013","unstructured":"Bi N, Shedden K, Zheng X, Kong F. Comparison of the effectiveness of radiofrequency ablation with stereotactic body radiation therapy in inoperable stage i non-small cell lung cancer: a systemic review and meta-analysis. Pract Radiat Oncol. 2013;3(2 Suppl 1):S19.","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"1826_CR2","doi-asserted-by":"publisher","first-page":"e803","DOI":"10.1016\/j.cllc.2018.06.001","volume":"19","author":"S Raman","year":"2018","unstructured":"Raman S, Yau V, Pineda S, Le LW, Lau A, Bezjak A, et al. Ultracentral tumors treated with stereotactic body radiotherapy: single-institution experience. Clin Lung Cancer. 2018;19(5):e803\u201310.","journal-title":"Clin Lung Cancer"},{"key":"1826_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.10.014","volume":"115","author":"ZD Horne","year":"2018","unstructured":"Horne ZD, Richman AH, Dohopolski MJ, Clump DA, Burton SA, Heron DE. Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers. Lung Cancer. 2018;115:1\u20134.","journal-title":"Lung Cancer"},{"issue":"7","key":"1826_CR4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","volume":"11","author":"H Tekatli","year":"2016","unstructured":"Tekatli H, Haasbeek N, Dahele M, De Haan P, Verbakel W, Bongers E, et al. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non-small cell lung cancer. J Thoracic Oncol. 2016;11(7):1081\u20139.","journal-title":"J Thoracic Oncol"},{"issue":"3","key":"1826_CR5","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.ijrobp.2018.06.118","volume":"102","author":"C Wang","year":"2018","unstructured":"Wang C, Sidiqi BU, Yorke ED, McKnight D, Dick-Godfrey R, Torres D, et al. Toxicity and local control in \u201cultra-central\u201d lung tumors treated with stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys. 2018;102(3):S10.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"30","key":"1826_CR6","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","volume":"24","author":"R Timmerman","year":"2006","unstructured":"Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1826_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1055\/s-0033-1342958","volume":"30","author":"T Hiraki","year":"2013","unstructured":"Hiraki T, Gobara H, Fujiwara H, Ishii H, Tomita K, Uka M, et al. Lung cancer ablation: complications. Semin Interv Radiol. 2013;30(2):169\u201375.","journal-title":"Semin Interv Radiol"},{"issue":"4","key":"1826_CR8","doi-asserted-by":"publisher","first-page":"W576","DOI":"10.2214\/AJR.11.6408","volume":"197","author":"M Kashima","year":"2011","unstructured":"Kashima M, Yamakado K, Takaki H, Kodama H, Yamada T, Uraki J, et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center\u2019s experiences. AJR Am J Roentgenol. 2011;197(4):W576\u201380.","journal-title":"AJR Am J Roentgenol"},{"issue":"19","key":"1826_CR9","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1002\/cncr.29507","volume":"121","author":"DE Dupuy","year":"2015","unstructured":"Dupuy DE, Fernando HC, Hillman S, Ng T, Tan AD, Sharma A, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer. 2015;121(19):3491\u20138.","journal-title":"Cancer"},{"issue":"10185","key":"1826_CR10","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051\u20138.","journal-title":"Lancet"},{"issue":"Suppl 3","key":"1826_CR11","doi-asserted-by":"publisher","first-page":"S468","DOI":"10.21037\/jtd.2018.01.130","volume":"10","author":"TR Cushman","year":"2018","unstructured":"Cushman TR, Gomez D, Kumar R, Likacheva A, Chang JY, Cadena AP, et al. Combining radiation plus immunotherapy to improve systemic immune response. J Thorac Dis. 2018;10(Suppl 3):S468\u201379.","journal-title":"J Thorac Dis"},{"key":"1826_CR12","unstructured":"Network NCC. NCCN clinical practice guidelines in oncology: non-small cell lung cancer (Version 8.2020). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"issue":"8","key":"1826_CR13","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1118\/1.3438081","volume":"37","author":"SH Benedict","year":"2010","unstructured":"Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078\u2013101.","journal-title":"Med Phys"},{"key":"1826_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 11-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1826_CR15","first-page":"237","volume":"27","author":"H Qiu","year":"2017","unstructured":"Qiu H, Ji J, Shao Z, Wang J, Ma G, Zhang L, et al. the efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in treatment of advanced lung cancer: a meta-analysis. J College Phys Surg Pakistan. 2017;27(4):237\u201345.","journal-title":"J College Phys Surg Pakistan"},{"issue":"3","key":"1826_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0360-3016(00)01453-X","volume":"49","author":"MA Manning","year":"2001","unstructured":"Manning MA, Zwicker RD, Arthur DW, Arnfield M. Biologic treatment planning for high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;49(3):839\u201345.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1826_CR17","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1378\/chest.127.6.2237","volume":"127","author":"J Ricke","year":"2005","unstructured":"Ricke J, Wust P, Wieners G, Hengst S, Pech M, Lopez H\u00e4nninen E, et al. CT-guided interstitial single-fraction brachytherapy of lung tumors: phase I results of a novel technique. Chest. 2005;127(6):2237\u201342.","journal-title":"Chest"},{"issue":"6","key":"1826_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s00066-008-1718-5","volume":"184","author":"N Peters","year":"2008","unstructured":"Peters N, Wieners G, Pech M, Hengst S, R\u00fchl R, Streitparth F, et al. CT-guided interstitial brachytherapy of primary and secondary lung malignancies: results of a prospective phase II trial. Strahlentherapie und Onkologie Organ der Deutschen Rontgengesellschaft [et al]. 2008;184(6):296\u2013301.","journal-title":"Strahlentherapie und Onkologie Organ der Deutschen Rontgengesellschaft [et al]"},{"issue":"3","key":"1826_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/JTO.0b013e318208c7a3","volume":"6","author":"N Tselis","year":"2011","unstructured":"Tselis N, Ferentinos K, Kolotas C, Schirren J, Baltas D, Antonakakis A, et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol. 2011;6(3):545\u201352.","journal-title":"J Thorac Oncol"},{"key":"1826_CR20","volume-title":"Radiobiology for the radiologist","author":"EJGA Hall","year":"2019","unstructured":"Hall EJGA. Radiobiology for the radiologist. 8th ed. Philadelphia: Wolters Kluwer; 2019.","edition":"8"},{"issue":"2","key":"1826_CR21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0360-3016(01)01823-5","volume":"52","author":"J Willner","year":"2002","unstructured":"Willner J, Baier K, Caragiani E, Tschammler A, Flentje M. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52(2):382\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7 Suppl 3","key":"1826_CR22","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","volume":"2","author":"H Onishi","year":"2007","unstructured":"Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thoracic Oncol. 2007;2(7 Suppl 3):S94-100.","journal-title":"J Thoracic Oncol"},{"issue":"6","key":"1826_CR23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.brachy.2019.08.003","volume":"18","author":"P Hass","year":"2019","unstructured":"Hass P, Mohnike K, Kropf S, Brunner TB, Walke M, Albers D, et al. Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies. Brachytherapy. 2019;18(6):823\u20138.","journal-title":"Brachytherapy"},{"issue":"11","key":"1826_CR24","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jama.2010.261","volume":"303","author":"R Timmerman","year":"2010","unstructured":"Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070\u20136.","journal-title":"JAMA"},{"issue":"3","key":"1826_CR25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.radonc.2013.01.004","volume":"106","author":"S Senthi","year":"2013","unstructured":"Senthi S, Haasbeek CJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol. 2013;106(3):276\u201382.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1826_CR26","doi-asserted-by":"publisher","first-page":"S340","DOI":"10.1016\/j.jtho.2016.11.369","volume":"12","author":"K Lindberg","year":"2017","unstructured":"Lindberg K, Bergstr\u00f6m P, Brustugun OT, Engelholm S, Grozman V, Hoyer M, et al. OA2405 the nordic HILUS-trial - first report of a phase II trial of SBRT of centrally located lung tumors. J Thoracic Oncol. 2017;12(1):S340.","journal-title":"J Thoracic Oncol"},{"key":"1826_CR27","unstructured":"Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wers\u00e4ll P, et al. The HILUS-trial; a prospective Nordic multi-center phase II study of ultra-central lung tumors treated with stereotactic body radiotherapy. J Thoracic Oncol."},{"issue":"4","key":"1826_CR28","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0003-4975(02)04681-7","volume":"75","author":"RI Whyte","year":"2003","unstructured":"Whyte RI, Crownover R, Murphy MJ, Martin DP, Rice TW, DeCamp MM Jr, et al. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg. 2003;75(4):1097\u2013101.","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"1826_CR29","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0360-3016(01)01516-4","volume":"50","author":"Y Negoro","year":"2001","unstructured":"Negoro Y, Nagata Y, Aoki T, Mizowaki T, Araki N, Takayama K, et al. The effectiveness of an immobilization device in conformal radiotherapy for lung tumor: reduction of respiratory tumor movement and evaluation of the daily setup accuracy. Int J Radiat Oncol Biol Phys. 2001;50(4):889\u201398.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1826_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/0973-1482.82914","volume":"7","author":"DN Sharma","year":"2011","unstructured":"Sharma DN, Rath GK, Thulkar S, Bahl A, Pandit S, Julka PK. Computerized tomography-guided percutaneous high-dose-rate interstitial brachytherapy for malignant lung lesions. J Cancer Res Ther. 2011;7(2):174\u20139.","journal-title":"J Cancer Res Ther"},{"issue":"5","key":"1826_CR31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/annonc\/mdv037","volume":"26","author":"T de Ba\u00e8re","year":"2015","unstructured":"de Ba\u00e8re T, Aup\u00e9rin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol. 2015;26(5):987\u201391.","journal-title":"Ann Oncol"},{"issue":"1","key":"1826_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00270-007-9225-0","volume":"31","author":"T Okuma","year":"2008","unstructured":"Okuma T, Matsuoka T, Yamamoto A, Oyama Y, Toyoshima M, Nakamura K, et al. Frequency and risk factors of various complications after computed tomography-guided radiofrequency ablation of lung tumors. Cardiovasc Intervent Radiol. 2008;31(1):122\u201330.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"1826_CR33","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jvir.2015.02.019","volume":"26","author":"BT Welch","year":"2015","unstructured":"Welch BT, Brinjikji W, Schmit GD, Callstrom MR, Kurup AN, Cloft HJ, et al. A national analysis of the complications, cost, and mortality of percutaneous lung ablation. J Vasc Intervent Radiol. 2015;26(6):787\u201391.","journal-title":"J Vasc Intervent Radiol"},{"issue":"1","key":"1826_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.injury.2006.07.006","volume":"38","author":"M Traub","year":"2007","unstructured":"Traub M, Stevenson M, McEvoy S, Briggs G, Lo SK, Leibman S, et al. The use of chest computed tomography versus chest X-ray in patients with major blunt trauma. Injury. 2007;38(1):43\u20137.","journal-title":"Injury"},{"issue":"1","key":"1826_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1755-7682-4-30","volume":"4","author":"HR Omar","year":"2011","unstructured":"Omar HR, Mangar D, Khetarpal S, Shapiro DH, Kolla J, Rashad R, et al. Anteroposterior chest radiograph vs chest CT scan in early detection of pneumothorax in trauma patients. Int Arch Med. 2011;4(1):30.","journal-title":"Int Arch Med."},{"key":"1826_CR36","doi-asserted-by":"crossref","unstructured":"Zaetta JM, Licht MO, Fisher JS, Avelar RL, Bio-Seal Study G. A lung biopsy tract plug for reduction of postbiopsy pneumothorax and other complications: results of a prospective, multicenter, randomized, controlled clinical study. J Vasc Intervent Radiol. 2010;21(8):1235-43.e1-3.","DOI":"10.1016\/j.jvir.2010.04.021"},{"issue":"2","key":"1826_CR37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s00270-016-1489-9","volume":"40","author":"JU Ahrar","year":"2017","unstructured":"Ahrar JU, Gupta S, Ensor JE, Mahvash A, Sabir SH, Steele JR, et al. Efficacy of a self-expanding tract sealant device in the reduction of pneumothorax and chest tube placement rates after percutaneous lung biopsy: a matched controlled study using propensity score analysis. Cardiovasc Intervent Radiol. 2017;40(2):270\u20136.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"1826_CR38","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1245\/s10434-008-9848-7","volume":"15","author":"JC Zhu","year":"2008","unstructured":"Zhu JC, Yan TD, Morris DL. A systematic review of radiofrequency ablation for lung tumors. Ann Surg Oncol. 2008;15(6):1765\u201374.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"1826_CR39","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jtho.2020.02.022","volume":"15","author":"MR Callstrom","year":"2020","unstructured":"Callstrom MR, Woodrum DA, Nichols FC, Palussiere J, Buy X, Suh RD, et al. Multicenter study of metastatic lung tumors targeted by interventional cryoablation evaluation (SOLSTICE). J Thoracic Oncol. 2020;15(7):1200\u20139.","journal-title":"J Thoracic Oncol"},{"issue":"8","key":"1826_CR40","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3109\/0284186X.2010.486796","volume":"49","author":"R Ruggieri","year":"2010","unstructured":"Ruggieri R, Naccarato S, Nahum AE. Severe hypofractionation: non-homogeneous tumour dose delivery can counteract tumour hypoxia. Acta Oncologica (Stockholm, Sweden). 2010;49(8):1304\u201314.","journal-title":"Acta Oncologica (Stockholm, Sweden)"},{"issue":"4","key":"1826_CR41","first-page":"119","volume":"5","author":"LT Flores","year":"2012","unstructured":"Flores LT, Bennett AV, Law EB, Hajj C, Griffith MP, Goodman KA. Patient-reported outcomes vs clinician symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res. 2012;5(4):119\u201324.","journal-title":"Gastrointest Cancer Res."},{"issue":"8","key":"1826_CR42","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","volume":"33","author":"M Di Maio","year":"2015","unstructured":"Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015;33(8):910\u20135.","journal-title":"J Clin Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01826-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-021-01826-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01826-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T21:05:49Z","timestamp":1623099949000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-021-01826-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1826"],"URL":"https:\/\/doi.org\/10.1186\/s13014-021-01826-1","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This investigation performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}